| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6487880 | Current Opinion in Biotechnology | 2014 | 7 Pages |
Abstract
- Proteins aggregate in a variety of ways, most of which are unwanted in drug products.
- Possible impacts on product quality include deliverability and immunogenicity.
- Controlling aggregation is difficult and is currently primarily phenomenological.
- Improved predictive approaches to control aggregation are needed.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Christopher J Roberts,